Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y263
UPID:
PLAP_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y263; Q53EU5; Q5VY33; Q9NUL8; Q9NVE9; Q9UF53; Q9Y5L1
Background:
Phospholipase A-2-activating protein plays a crucial role in protein ubiquitination, sorting, and degradation, associating with VCP to facilitate synaptic vesicle recycling and macroautophagy. It is pivotal in cerebellar Purkinje cell development and enhances prostaglandin E2 biosynthesis through regulation of phospholipase A2 activities.
Therapeutic significance:
Linked to a neurodevelopmental disorder characterized by progressive microcephaly, spasticity, and brain anomalies, understanding the role of Phospholipase A-2-activating protein could open doors to potential therapeutic strategies.